1,3,3,-trimethylpyrrolidine | 16911-20-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1,3,3,-trimethylpyrrolidine
• 英文别名: 1,3,3-trimethyl-pyrrolidine；1,3,3-Trimethyl-pyrrolidin；1,3,3-Trimethylpyrrolidine
• CAS: 16911-20-9
• 化学式: C₇H₁₅N
• 分子量: 113.203
• InChiKey: WACYTCDCBQXUAW-UHFFFAOYSA-N

物化性质

• 沸点：
  77-79 °C
• 密度：
  0.819±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,2-二甲基琥珀酸 在 四氢呋喃 、 lithium aluminium tetrahydride 、 水 作用下， 生成 1,3,3,-trimethylpyrrolidine
  参考文献：
  名称：

  Unsaturated Amines. I. Determination of the Proximity of Nitrogen to a Double Bond by Infrared Absorption Spectra^1,2

  摘要：

  DOI：

  10.1021/ja01639a052

文献信息

• ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS
  申请人：UOP LLC

  公开号：US20160159760A1

  公开（公告）日：2016-06-09

  Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained.

  描述了新型的1-oxa-4-azonium环己烷盐。这些化合物可用作结构导向剂，并且克服了与OSDA合成和随后的沸石合成相关许多典型问题。还描述了从各种起始材料合成1-oxa-4-azonium环己烷盐的方法。 将取代的烃加入水中形成混合物，然后加入1-oxa-4-azacyclohexane衍生物。搅拌反应混合物，直到获得含有1-oxa-4-azonium环己烷盐的溶液。
• New compounds, pharmaceutical compositions and uses thereof
  申请人：ROTH Gerald Juergen

  公开号：US20120214782A1

  公开（公告）日：2012-08-23

  The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及公式I的新化合物，以及它们作为药物的用途，它们的治疗用途的方法，以及含有它们的药物组合物。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2015026792A1

  公开（公告）日：2015-02-26

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包括一种或多种抗病毒化合物的药物组合物，以及合成这些化合物的方法。本文还披露了使用一种或多种小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP3305789A1

  公开（公告）日：2018-04-11

  The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3A R3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

  本发明提供了一种具有抗病毒活性的新型化合物，特别是具有抑制HIV复制活性的化合物和含有该化合物的药物。该化合物由以下式表示： 其中A3为CR3A、CR3A R3B、N或NR3C；R3A、R3B、R4A和R4B分别独立地为氢原子、卤素、氰基、取代或未取代的烷基、取代或未取代的炔基，或取代或未取代的非芳香碳环烷基；R3C为氢原子、取代或未取代的烷基，或取代或未取代的非芳香碳环烷基；环T1为取代或未取代的含氮非芳香杂环；R1为氢原子、卤素、氰基，或取代或未取代的烷基；R2分别为取代或未取代的烷基或类似物；n为1或2；R3为取代或未取代的芳香碳环烷基或类似物；R4为氢原子或羧基保护基。
• [EN] DIHYDROPYRROLOPYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIHYDROPYRROLOPYRIMIDINE
  申请人：PFIZER

  公开号：WO2015155624A1

  公开（公告）日：2015-10-15

  The present invention relates to compounds of formula (X) or pharmaceutically acceptable salts thereof, wherein R1 - R50, a, b, d, e, f, g, h, i, j, k, I, o, p, q, r, s, t, u, y, and z are defined herein. The novel dihydropyrrolopyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（X）的化合物或其药用可接受的盐，其中R1-R50，a，b，d，e，f，g，h，i，j，k，I，o，p，q，r，s，t，u，y和z在此处定义。这些新颖的二氢吡咯嘧啶衍生物在治疗哺乳动物中的异常细胞生长，如癌症方面是有用的。另外，还涉及含有这些化合物的药物组合物以及在治疗哺乳动物中的异常细胞生长中使用这些化合物和组合物的方法。